MIRA Reports Positive Preclinical Data for Oral Obesity Drug Candidate SKNY-1

MIRA Pharmaceuticals reported successful preclinical data for obesity drug candidate SKNY-1, demonstrating favorable oral bioavailability and brain penetration. These findings strengthen the development profile of a potential once-daily oral therapy for both obesity and addiction.